Aa
tnf 8 years on hiv+hbv hbsag decline
http://www.hivandhepatitis.com/hepatitis-b/hepatitis-b-topics/hbv-treatment/3328-aasld-long-term-tenofovir-for-hivhbv-coinfection
HBsAg Changes
In the second study, Roeland Zoutendijk from Erasmus Medical Center in Rotterdam and colleagues looked at HBsAg changes during long-term tenofovir treatment, with the aim of learning more about HBV clearance.
This multicenter analysis included 104 HIV/HBV coinfected patients treated with ART regimens containing tenofovir. Again, most (about 90%) were men, the age range was similar, and about 60% were white; about two-thirds were HBeAg positive at baseline.
The investigators measured HBsAg levels at baseline, month 6, and then annually; the median duration of follow-up was 56 months (range 8-97 months). HBsAg clearance is generally considered a cure, though "occult: or hidden HBV may remain.
Results
At baseline, HBsAg was significantly higher among HBeAg positive patients compared with HBeAg negative people (4.6 vs 2.8 log IU/mL).
12 HBeAg positive patients (18%) achieved HBeAg seroconversion.
5 HBeAg positive people (8%) and 3 HBeAg negative people (also 8%) achieved HBsAg loss.
HBsAg levels declined steadily among HBeAg positive people, but the decrease was smaller among HBeAg negative patients.
In HBeAg positive patients, immune reconstitution -- as indicated by higher CD4 cell counts at months 6 and 12 -- was correlated with HBsAg decline.
HBeAg positive patients with month 6 HBsAg levels 100 IU/mL.
Extrapolating these numbers, the researchers estimated that the estimated median time to HBsAg loss would be about 18 years for HBeAg positive people and 41 years for HBeAg negative patients.
"HBsAg levels declined steadily, particularly in HBeAg positive patients, during [tenofovir treatment] up to 8 years in HIV/HBV coinfected patients," the investigators concluded. "On-treatment correlation between CD4 count and HBsAg decline indicates a possible role of immune reconstitution in HBsAg loss," they suggested.
HBsAg Changes
In the second study, Roeland Zoutendijk from Erasmus Medical Center in Rotterdam and colleagues looked at HBsAg changes during long-term tenofovir treatment, with the aim of learning more about HBV clearance.
This multicenter analysis included 104 HIV/HBV coinfected patients treated with ART regimens containing tenofovir. Again, most (about 90%) were men, the age range was similar, and about 60% were white; about two-thirds were HBeAg positive at baseline.
The investigators measured HBsAg levels at baseline, month 6, and then annually; the median duration of follow-up was 56 months (range 8-97 months). HBsAg clearance is generally considered a cure, though "occult: or hidden HBV may remain.
Results
At baseline, HBsAg was significantly higher among HBeAg positive patients compared with HBeAg negative people (4.6 vs 2.8 log IU/mL).
12 HBeAg positive patients (18%) achieved HBeAg seroconversion.
5 HBeAg positive people (8%) and 3 HBeAg negative people (also 8%) achieved HBsAg loss.
HBsAg levels declined steadily among HBeAg positive people, but the decrease was smaller among HBeAg negative patients.
In HBeAg positive patients, immune reconstitution -- as indicated by higher CD4 cell counts at months 6 and 12 -- was correlated with HBsAg decline.
HBeAg positive patients with month 6 HBsAg levels 100 IU/mL.
Extrapolating these numbers, the researchers estimated that the estimated median time to HBsAg loss would be about 18 years for HBeAg positive people and 41 years for HBeAg negative patients.
"HBsAg levels declined steadily, particularly in HBeAg positive patients, during [tenofovir treatment] up to 8 years in HIV/HBV coinfected patients," the investigators concluded. "On-treatment correlation between CD4 count and HBsAg decline indicates a possible role of immune reconstitution in HBsAg loss," they suggested.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
